IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS
EHA Learning Center, Félix López Cadenas, 181605
VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS): A PHASE 1/COHORT EXPANSION STUDY
EHA Learning Center, Meagan Jacoby, 181606
ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE
EHA Learning Center, Santiago Barrio, 181607
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA
EHA Learning Center, Matteo Marchesini, 181608
PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.
EHA Learning Center, Mattia D'Agostino, 181609
TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA
EHA Learning Center, Salomon Manier, 181610
DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS TO IMIDS
EHA Learning Center, Konstantinos Dimopoulos, 181611
MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANDIDATE ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA
EHA Learning Center, Raquel Ordoñez, 181612
CLINICAL IMPLICATIONS OF CLONAL CD34+ CELLS IN STEM CELL HARVEST FROM PATIENTS WITH PLASMA CELL DYSCRASIAS
EHA Learning Center, Sneha CHITRE, 181613
PATHOPHYSIOLOGICAL FUNCTIONS AND CLINICAL IMPACT OF THE NEW IMMUNORECEPTOR SLAMF3 IN MULTIPLE MYELOMA
EHA Learning Center, Mariko Ishibashi, 181614
TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE (ADC), STRO-001
EHA Learning Center, Arturo Molina, 181615
GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING
EHA Learning Center, Isabel Cuenca, 181616
IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY
EHA Learning Center, Sigrun Thorsteinsdottir, 181617
PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Moritz Binder, 181618
LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB
EHA Learning Center, Philip L. McCarthy, 181619
UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Roman Hajek, 181620
EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF POLLUX
EHA Learning Center, Meletios A. Dimopoulos, 181621
DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (≥75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES
EHA Learning Center, María-Victoria Mateos, 181622
ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL
EHA Learning Center, Heinz Ludwig, 181623
EVALUATION OF GROWTH DIFFERENTIATION FACTOR-1 (GDF15) AS A NEW BIOMARKER FOR RENAL OUTCOMES IN DIFFERENT COHORTS OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Efstathios Kastritis, 181624
AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ICD) IN TRANSPLANT-INELIGIBLE PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
EHA Learning Center, Meletios A Dimopoulos, 181625
THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE (MP) FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)
EHA Learning Center, Jesus F. San Miguel, 181626
FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB (MPV) IN PATIENTS ≥ 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY
EHA Learning Center, Sonja Zweegman, 181627
THE EUROPEAN MYELOMA NETWORK EMN09 STUDY: CARFILZOMIB, BENDAMUSTINE, AND DEXAMETHASONE (CBD) IS EFFICIENT AND SAFE IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA
EHA Learning Center, M. Gramatzki, 181628
CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP
EHA Learning Center, Ute Hegenbart, 181629
MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE (POM) PLUS LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)
EHA Learning Center, Pieter Sonneveld, 181630
PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B KEYNOTE-013 STUDY
EHA Learning Center, David Siegel, 181631
ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM.
EHA Learning Center, Zoe Van de Wyngaert, 181632
SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Jinchul Kim, 181633
A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK
EHA Learning Center, Ovini GAMAGE, 181634
SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES
EHA Learning Center, Thomas Dejoie, 181635
THE CONNECT MM REGISTRY: IMPACT OF THE CYTOGENETIC ABNORMALITY T(11;14) ON SURVIVAL OUTCOMES IN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Cristina J. Gasparetto, 181636
RAS-PATHWAY MUTATION PATTERNS DEFINE EPIGENETIC SUBCLASSES IN JUVENILE MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Daniel Lipka, 181637
CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY
EHA Learning Center, Barbara , 181638
MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM - UNCLASSIFIABLE (MDS/MPN-U)
EHA Learning Center, Prithviraj Bose, 181639
GENOME WIDE DNA METHYLATION PROFILING IS PREDICTIVE OF OUTCOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Elliot Stieglitz, 181640
LEUKEMIC TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS: IS NGS PROFILE THE BEST PROGNOSTIC BIOMARKER?
EHA Learning Center, Venton Geoffroy, 181641
INCIDENCE AND OUTCOME OF SECONDARY NON HEMATOLOGICAL CANCERS IN ADULT PATIENTS WITH MASTOCYTOSIS
EHA Learning Center, M Bonifacio, 181642
HIGH WBC COUNT WAS THE RISK FACTOR FOR SURVIVAL IN PATIENTS WITH CSF3R- MUTATED CHRONIC NEUTROPHILIC LEUKEMIA
EHA Learning Center, Qian Jiang, 181643
CLINICAL PHENOTYPE AND OUTCOME OF ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC MYELOFIBROSIS DIAGNOSED ACCORDING TO THE REVISED 2016 WHO DIAGNOSTIC CRITERIA
EHA Learning Center, Michele Ciboddo, 181644
VALIDATION OF THE REVISED IPSET-THROMBOSIS SCORE IN 734 PATIENTS WITH WHO 2016-DEFINED ESSENTIAL THROMBOCYTHEMIA. REPORT OF THE REGISTRO ITALIANO TROMBOCITEMIE (RIT)
EHA Learning Center, Luigi Gugliotta, 181645
CORRELATIONS BETWEEN INFLAMMATORY BIOMARKERS AND INDIVIDUAL SYMPTOMS EXPRESSED BY MYELOFIBROSIS PATIENTS IN THE COMFORT-I TRIAL: ANALYSIS OF BASELINE ASSOCIATIONS AND CHANGES OVER TIME
EHA Learning Center, Holly L Geyer, 181646
NOVEL HETEROZYGOUS ITGB3 P.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN ΑIIBΒ3 CAUSES AUTOSOMAL DOMINANT MACROTHROMBOCYTOPENIA WITH ABNORMAL ΑIIBΒ3 LOCALIZATION
EHA Learning Center, Naohiro Miyashita, 181647
CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG
EHA Learning Center, Jose Maria Bastida Bermejo, 181648
DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRESPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Shixuan wang, 181649
A DECREASED INTRACELLULAR S1P LEVEL AND S1P RECEPTORS EXPRESSED ON MEGAKARYOCYTES POSSIBLY CONTRIBUTE TO DEFECTIVE PROPLATELETS FORMATION IN IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Xiao-Hui Zhang, 181650
ANTIBODY MEDIATED GLYCAN MODIFICATION: A POTENTIAL ROLE IN PLATELET DESTRUCTION IN AUTOIMMUNE THROMBOCYTOPENIA
EHA Learning Center, Irene Marini, 181651
NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED THROMBOCYTOPENIA
EHA Learning Center, Patrizia Noris, 181652
A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
EHA Learning Center, John Grainger, 181654
NOVEL THIENOPYRIDINES AS POTENT PLATELET INHIBITORS: FUTURE TREATMENTS FOR PLATELET HYPERACTIVITY DISORDERS?
EHA Learning Center, Naif Binsaleh, 181655
PATIENT-REPORTED OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION BEFORE AND DURING TREATMENT WITH ECULIZUMAB: RESULTS FROM THE INTERNATIONAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA REGISTRY
EHA Learning Center, Petra Muus, 181656
ECONOMIC IMPACT OF INTRODUCING AGE-ADJUSTED D-DIMER CUT-OFF LEVELS IN THE DIAGNOSIS STRATEGY OF VENOUS THROMBOEMBOLISM
EHA Learning Center, Pierre Toulon, 181657
IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME.
EHA Learning Center, Silvy Lachance, 181658
ACUTE MYELOID LEUKEMIA (AML) TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US COMMERCIALLY-INSURED POPULATION
EHA Learning Center, Karen Chung, 181659
HEALTH-RELATED QUALITY OF LIFE IN AL AMYLOIDOSIS PATIENTS WITH NERVOUS SYSTEM INVOLVEMENT
EHA Learning Center, tiffany quock, 181660
ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT QUALITY OF LIFE
EHA Learning Center, Wendy Ingram, 181661
THE BUDGET IMPACT OF TREATMENT-FREE REMISSION FOR FIRST-LINE NILOTINIB OR GENERIC IMATINIB IN TREATING CHRONIC PHASE PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Patricia Brandt, 181662
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (>65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
EHA Learning Center, Javier De La Rubia, 181663
NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY
EHA Learning Center, Robyn , 181664
DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE
EHA Learning Center, Aliki XOCHELLI, 181665
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Jonathan Canaani, 181666
BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS
EHA Learning Center, Madlen Jentzsch, 181667
THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS
EHA Learning Center, Alice Bertaina, 181668
EXCELLENT RESPONSE, LOW TRM AND GOOD SURVIVAL IN PATIENTS WITH THERAPY-REFRACTORY AGVHD AFTER TREATMENT WITH EQUIPOTENT MSCS OF A SERUM-FREE MSC-BANK GENERATED FROM POOLED BM-MNCS OF MULTIPLE DONORS
EHA Learning Center, Selim Kuci, 181669
HIGHER PEAK TACROLIMUS CONCENTRATIONS AFTER ALLOGENEIC TRANSPLANTATION INCREASE THE RISK OF ENDOTHELIAL CELL DAMAGE COMPLICATIONS
EHA Learning Center, Takanobu Morishita, 181670
IMPACT OF CONDITIONING REGIMEN ON OUTCOMES OF T-REPLETE HAPLO-IDENTICAL TRANSPLANTATION FOR PATIENTS OVER 45 YEARS-OLD WITH AML: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Daniela Nasso, 181671
ROLE OF UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A DECISION ANALYSIS
EHA Learning Center, Shigeo Fuji, 181672
INTERFERON-Α IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Xiao-Dong Mo, 181674
COMPARABLE LONG-TERM OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR OLDER PATIENTS (AGE ≥50 YEARS) WITH AML FROM SIBLING AND MATCHED UNRELATED DONORS. A REPORT ON BEHALF OF THE ALWP OF EBMT.
EHA Learning Center, A Shimoni, 181675
IMPACT OF AZACITIDINE PRETREATMENT ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME
EHA Learning Center, Jun Aoki, 181676
LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT
EHA Learning Center, Yue Han, 181677
QUANTITATIVE PROTEOMICS OF PLASMA EXTRACELLULAR VESICLES TO IDENTIFY NOVEL BIOMARKERS OF CLINICAL SEVERITY FOR HBE/Β-THALASSEMIC PATIENTS
EHA Learning Center, Janejira Kittivorapart, 181678
A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE MODEL OF BETA-THALASSEMIA
EHA Learning Center, Lucia de Franceschi, 181679
MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON THE BETA THALASSEMIA PHENOTYPE?
EHA Learning Center, Michela Grosso, 181680
SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR THALASSEMIA MAJOR
EHA Learning Center, Antonella Meloni, 181681
VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES
EHA Learning Center, thidarat suksangpleng, 181682
TRANSIENT ELASTOGRAPHY IN NON TRANSFUSION DEPENDENT THALASSEMIA: A SUCCESSFUL TOOL TO ASSESS AND MONITORING LIVER FIBROSIS
EHA Learning Center, Alessia Marcon, 181683
INCREASING INCIDENCE OF MALIGNACIES IN AGING THALASSEMIC PATIENTS: A SINGLE INSTITUTION'S LONGITUDINAL EXPERIENCE
EHA Learning Center, Elpida REPOUSI, 181684
SAFETY AND EFFICACY OF EARLY START WITH SUBOPTIMAL DOSE OF DEFERIPRONE IN MINIMALLY TRANSFUSED INFANTS WITH TRANSFUSION DEPENDENT THALASSEMIA: A RANDOMIZED TRIAL
EHA Learning Center, Amira Adly, 181685
LONGITUDINAL PROSPECTIVE MRI STUDY IN PEDIATRIC PATIENTS WITH THALASSEMIA MAJOR
EHA Learning Center, Antonella Meloni, 181686
LONG TERM FOLLOW-UP OF A COHORT OF WELL TREATED Β-THALASSEMIA MAJOR PATIENTS BY MULTI-ORGAN R2* MAGNETIC RESONANCE IMAGING
EHA Learning Center, Gian Luca Forni, 181687
DEVELOPMENT OF HTLV-1 HYPERIMMUNE GLOBULINS AGAINST HTLV-1 INFECTION
EHA Learning Center, Takuo Mizukami, 181688
THE CONTAMINATION OF TUMOR CELLS IN THE APHERESIS MATERIAL DOES NOT PREDICT THE RESPONSE OF MULTIPLE MYELOMA PATIENTS TO AUTOLOGOUS TRANSPLANTATION
EHA Learning Center, Maria Luisa Lozano, 181689
EVALUATION OF THERAPEUTIC PLASMA EXCHANGE AT A TERTIARY LONDON HOSPITAL
EHA Learning Center, Rachel Moll, 181690
A COMPREHENSIVE PROTEOMICS STUDY ON PLATELET CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND MIRASOL PATHOGEN REDUCTION TECHNOLOGY
EHA Learning Center, Laura Gutierrez, 181691
USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING
EHA Learning Center, Dana Warcel, 181692
SCREENING OF TRANSFUSION PRODUCTS FOR PRION DISEASES USING APTAMERS AND TUNABLE RESISTIVE PULSE SENSING
EHA Learning Center, Matthew Healey, 181693
NOVEL SMALL MOLECULE INHIBITORS CO-TARGETING CK1A AND P-TEF-B DISRUPT SUPER-ENHANCERS AND ERADICATE ACUTE MYELOID LEUKEMIA IN A MOUSE MODEL
EHA Learning Center, Yinon Ben-Neriah, 183935
TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP
EHA Learning Center, Peter Borchmann, 181437
REVERSIBLE PHARMACOLOGICAL TARGETING OF RHOA ALLOWS IMPROVED STORAGE, SURVIVAL AND HEMOSTATIC ACTIVITY OF PLATELETS IN VITRO AND IN VIVO, IN MICE AND IN PRIMATES.
EHA Learning Center, Shailaja Hegde, 181436
EXPOSURE TO INFECTION TRIGGERS PAX5 AND ETV6-RUNX1 CHILDHOOD BCP-ALL
EHA Learning Center, Julia Hauer, 181435
RE-CREATING HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN (HPFH) WITH CRISPR/CAS9 TO TREAT SICKLE CELL DISEASE (SCD) AND BETA-THALASSEMIA (BETA-THAL)
EHA Learning Center, Bill Lundberg, 181434
BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS
EHA Learning Center, Mattia Algeri, 181433
Myeloid malignancies
EHA Learning Center, Mario Cazzola, 184436
Novel Treatment Strategies In Waldenström's Macroglobulinemia
EHA Learning Center, Efstathios Kastritis, 184439
Risk Adapted Treatment Of CMML
EHA Learning Center, Eric Padron, 184445
Targeted next generation sequencing to improve diagnosis of rare anaemia
EHA Learning Center, Barnaby Clark, 184448
New approaches to MM
EHA Learning Center, Jesus F. San Miguel, 192907
What's new in the 2016 WHO lymphoma classification?
EHA Learning Center, Steven Swerdlow, 184435
Molecular Biology Of Waldenström's Disease
EHA Learning Center, Steven Treon, 184438